Form 4: Guardant Health CTO Granted 23,856 RSUs

Guardant Health's Chief Technology Officer, Darya Chudova, was granted 23,856 Restricted Stock Units with a three-year vesting schedule.

Summary

• Darya Chudova, Chief Technology Officer (CTO) of Guardant Health, Inc. (GH), was granted 23,856 Restricted Stock Units (RSUs).
• The grant date for these RSUs is March 11, 2026.
• The RSUs will vest over a three-year period.
• 33% of the shares subject to the award will vest on April 1, 2027.
• The remaining 67% of the shares will vest in equal quarterly installments over the subsequent two-year period.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting the company's commitment to retaining key executive talent and aligning their incentives with long-term shareholder value through equity compensation.

Positives

• The grant of 23,856 Restricted Stock Units to the Chief Technology Officer aligns management incentives with long-term shareholder value.
• The three-year vesting schedule encourages retention of key executive talent within the company.

Negatives

• No immediate cash compensation or direct stock purchase is involved, as this is an RSU grant with a future vesting schedule.

Future Outlook

The Restricted Stock Unit grant with a three-year vesting schedule indicates a long-term commitment to the company by the Chief Technology Officer and represents a strategy to retain key executive talent.

Industry Context

StockSavvy.ai notes that equity grants, particularly Restricted Stock Units with multi-year vesting, are a standard practice in the biotechnology and healthcare technology sectors to attract and retain high-caliber executive talent, aligning their interests with long-term company performance and shareholder value. This is consistent with compensation strategies seen across the industry for key technical leadership roles.

Comparison to Industry Standards

• The grant of 23,856 RSUs to a CTO is a common form of executive compensation in growth-oriented biotech and health-tech companies, comparable to practices at peers like Illumina or Exact Sciences, where equity forms a significant portion of total compensation to incentivize innovation and long-term value creation.
• A three-year vesting schedule is standard for RSU grants, similar to what is observed at companies such as Foundation Medicine or Natera, ensuring executive retention and commitment over a strategic planning horizon.

Corporate Governance

Related Party Transactions

• Grant of 23,856 Restricted Stock Units to Chief Technology Officer Darya Chudova, which is a form of executive compensation.

Stakeholder Impact

• Shareholders: Potential positive impact through better alignment of executive incentives with long-term company performance and retention of key talent.
• Employees: May signal stability in executive leadership.

Next Steps

• Vesting of 33% of RSUs on April 1, 2027.
• Subsequent quarterly vesting of the remaining 67% over the following two years.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a key executive, which is a standard compensation practice and does not provide new information that would significantly alter the fundamental investment thesis for Guardant Health. It reinforces executive retention but does not indicate a strong buy or sell signal on its own.

Keywords

Guardant Health, GH, Restricted Stock Units, RSU, Insider Transaction, Darya Chudova, Chief Technology Officer, Executive Compensation, Form 4, Equity Grant